New molecular entity: Rifaximin

News
Article

This nonsystemic, gastrointestinal-selective oral antibiotic exerts its effect by binding to the beta-subunit of bacterial DNA- dependent RNA polymerase. Rifaximin was approved on May 25, 2004, for the treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli in patients aged 12 years and older.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.